New Zealand markets open in 3 hours 7 minutes

Daré Bioscience, Inc. (DARE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3926+0.0308 (+8.51%)
As of 12:45PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.3618
Open0.3490
Bid0.3903 x 1100
Ask0.3949 x 1000
Day's range0.3610 - 0.3990
52-week range0.2700 - 1.1500
Volume1,359,071
Avg. volume583,926
Market cap38.696M
Beta (5Y monthly)1.03
PE ratio (TTM)N/A
EPS (TTM)-0.4800
Earnings date28 Mar 2024 - 01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • GlobeNewswire

    Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

    Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of the sexual experience Continuing to work toward Phase 3 pivotal study There are no FDA-approved treatments for female sexual arousal disorder SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that additional data from the e

  • GlobeNewswire

    Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

    There are no FDA-approved treatments for female sexual arousal disorderSAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the successful completion of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting advancement of Sildenafil Cream, 3.6% (Sil

  • GlobeNewswire

    Daré Bioscience Announces Executive Team and Board of Directors Changes

    SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors t